IRIS
GENTILE, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 10.019
NA - Nord America 7.213
SA - Sud America 2.990
EU - Europa 2.890
Continente sconosciuto - Info sul continente non disponibili 473
AF - Africa 420
OC - Oceania 10
AN - Antartide 1
Totale 24.016
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.755
SG - Singapore 3.864
BR - Brasile 2.184
CN - Cina 1.972
VN - Vietnam 1.756
IT - Italia 1.303
BD - Bangladesh 585
HK - Hong Kong 404
FR - Francia 402
KR - Corea 315
AR - Argentina 287
DE - Germania 231
IN - India 186
FI - Finlandia 183
IQ - Iraq 156
MX - Messico 152
CA - Canada 130
EC - Ecuador 130
GB - Regno Unito 128
RU - Federazione Russa 112
NL - Olanda 111
ZA - Sudafrica 109
CO - Colombia 101
ID - Indonesia 96
PK - Pakistan 82
VE - Venezuela 80
TR - Turchia 73
MA - Marocco 71
UA - Ucraina 71
AT - Austria 70
CL - Cile 64
UZ - Uzbekistan 58
PY - Paraguay 54
MY - Malesia 47
DZ - Algeria 42
PH - Filippine 42
SA - Arabia Saudita 42
JO - Giordania 40
PL - Polonia 40
ES - Italia 39
EG - Egitto 38
TN - Tunisia 36
UY - Uruguay 35
NP - Nepal 34
JP - Giappone 29
JM - Giamaica 28
PE - Perù 28
SE - Svezia 27
BO - Bolivia 26
KE - Kenya 26
CR - Costa Rica 25
KZ - Kazakistan 25
AE - Emirati Arabi Uniti 24
AZ - Azerbaigian 24
SN - Senegal 22
HN - Honduras 21
IL - Israele 21
CZ - Repubblica Ceca 20
DO - Repubblica Dominicana 20
KG - Kirghizistan 20
PA - Panama 18
ET - Etiopia 17
OM - Oman 17
AL - Albania 16
BG - Bulgaria 16
GT - Guatemala 15
LB - Libano 14
NI - Nicaragua 14
PS - Palestinian Territory 13
TH - Thailandia 13
BA - Bosnia-Erzegovina 11
RO - Romania 11
RS - Serbia 11
QA - Qatar 10
TT - Trinidad e Tobago 10
IE - Irlanda 9
NG - Nigeria 9
AO - Angola 8
SK - Slovacchia (Repubblica Slovacca) 8
AU - Australia 7
HU - Ungheria 7
LT - Lituania 7
SY - Repubblica araba siriana 7
BE - Belgio 6
BH - Bahrain 6
BY - Bielorussia 6
CI - Costa d'Avorio 6
GE - Georgia 6
GR - Grecia 6
HR - Croazia 6
KH - Cambogia 6
KW - Kuwait 6
SV - El Salvador 6
AM - Armenia 5
MU - Mauritius 5
BB - Barbados 4
CH - Svizzera 4
GA - Gabon 4
LY - Libia 4
MK - Macedonia 4
Totale 23.454
Salva come PNG Salva come JPEG
Città #
Singapore 1.480
San Jose 1.191
Council Bluffs 1.168
Dallas 766
Ashburn 677
Boardman 650
Ho Chi Minh City 645
Hefei 510
Hong Kong 396
Hanoi 368
Beijing 346
Florence 324
Seoul 313
Lauterbourg 306
Shanghai 229
São Paulo 209
New York 146
Santa Clara 146
Helsinki 137
Los Angeles 131
Rome 104
Milan 102
Da Nang 93
Haiphong 92
Munich 83
Rio de Janeiro 72
Ogden 68
Guangzhou 60
Boydton 55
Amsterdam 53
Quito 53
Dhaka 52
Baghdad 51
Tashkent 50
Brasília 49
Columbus 49
Phoenix 49
Sesto Fiorentino 47
Noto 45
Vienna 45
Chicago 44
Brooklyn 42
Biên Hòa 41
Belo Horizonte 39
Johannesburg 38
Buffalo 37
Frankfurt am Main 37
Mexico City 36
Amman 35
Montreal 35
Tianjin 34
Guayaquil 33
Rende 30
Warsaw 30
Naples 29
Buenos Aires 28
Caracas 28
The Dalles 28
Wuhan 28
Atlanta 27
Curitiba 27
Hải Dương 27
Lahore 27
Montevideo 27
Omaha 27
Orem 27
Porto Alegre 27
Asunción 26
London 26
Bari 25
Santiago 25
Thái Nguyên 25
Can Tho 24
Charlotte 24
Ninh Bình 24
Turku 24
Mumbai 23
San Francisco 23
Seattle 23
Tokyo 23
Bogotá 22
Campinas 22
Dakar 22
Fortaleza 22
Kuala Lumpur 22
Toronto 22
Chennai 21
Erbil 21
Lappeenranta 21
Nairobi 21
Stockholm 21
Washington 21
San José 20
Turin 20
Baku 19
Chandler 19
Guarulhos 19
Medellín 19
Nuremberg 19
Recife 19
Totale 13.005
Salva come PNG Salva come JPEG
Nome #
Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study 185
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? 183
Human pluripotent stem cells identify molecular targets of trisomy 12 in chronic lymphocytic leukemia patients 183
CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy 183
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 153
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 144
Vaccination in Multiple Myeloma: Challenges and Strategies 144
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 134
A novel phage display based platform for exosome diversity characterization 133
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma 132
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 131
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 131
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 130
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? 129
Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax 128
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 127
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 127
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 127
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 125
Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay 122
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 120
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 119
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives 118
The role of corticosteroids in the current treatment paradigm for myelofibrosis 118
Momelotinib in myelofibrosis 118
Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma 115
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience 115
TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions 115
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 114
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 114
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing 114
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies 114
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 113
The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients 113
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report 113
The use of ibrutinib before and after allogeneic stem cell transplantation 112
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells 112
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 112
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 111
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair? 110
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 110
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 108
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia 108
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 107
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 107
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 106
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study 104
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 103
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 103
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 102
Iron chelation therapy 101
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement 101
Belantamab mafodotin in multiple myeloma 101
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 100
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 98
Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking? 97
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 96
A progression-risk score to predict treatment free survival for early stage chronic lymphocytic leukemia patients. 96
LINC00152 expression in normal and Chronic Lymphocytic Leukemia B cells 95
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 95
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study 95
Comparative Analysis of Bispecific Antibodies and CAR T‐Cell Therapy in Follicular Lymphoma 95
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 95
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 94
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study 94
Selinexor in multiple myeloma 94
Teclistamab-cqyv in multiple myeloma 94
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement 94
An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma 94
Acalabrutinib in chronic lymphocytic leukemia 93
Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. 93
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement 93
Ibrutinib in patients over 80 with chronic lymphocytic leukemia: a multicenter Italian cohort 93
A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide 93
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 92
Myelodysplastic syndromes with ring sideroblasts 91
A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL) 91
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: non-traditional factors may play a role in clinical practice 91
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant 91
Predominant VH1-69 IgBCR Clones Show Higher Expression of CD5 in Heterogeneous Chronic Lymphocytic Leukemia Populations 91
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study 90
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 90
Cerebral pheohyphomycosis due to curvularia species 89
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 89
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 89
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant 88
Advances and Challenges in Quizartinib‐Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies 88
Elotuzumab in multiple myeloma 88
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study 87
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary Immune Thrombocytopenia: a randomised trial 87
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma 87
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 86
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study 85
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort 85
Unraveling Obesity and Multiple Myeloma: Insights from Epidemiology and Molecular Mechanisms 85
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study 84
Ivosidenib in acute myeloid leukemia 84
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes 84
Rilzabrutinib for the Treatment of Immune Thrombocytopenia 83
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 82
Totale 10.770
Salva come PNG Salva come JPEG
Categoria #
all - tutte 140.396
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 140.396
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202222 0 0 0 0 2 0 0 6 1 1 5 7
2022/2023442 6 5 3 11 8 5 279 22 19 20 50 14
2023/20241.536 35 36 245 194 97 153 80 48 120 50 67 411
2024/20254.157 179 611 112 151 165 137 88 170 706 355 405 1.078
2025/202616.164 2.053 814 1.195 1.365 2.860 1.008 1.998 827 1.008 1.232 817 987
2026/20271.685 1.037 488 160 0 0 0 0 0 0 0 0 0
Totale 24.016